DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* NEOVACS *


 

1993 - IDF
Paris
www.neovacs.com

 

Discovery, Immunology
Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids
Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases
Clients: Prescribers
contact@neovacs.com

Age: 23 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough]
Sc.Dir.-CSO: Grouard-Vogel (Géraldine) [Pharm.D., Ph.D. immunology, ex-Aventis Pasteur, Walter Reed Army Institute]
Pharm.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur]
Fin.Dir.-CFO:
BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting]
Comm.Dir.: Hocdée-Leroy (Florence) [EM Lyon, ex-Rhône-Poulenc, KBC Securities, Grosvenor]
Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis, OTC Asset Management
note : at the end of December 2010, Novartis shares account for 26.6%

Turnover (M€) : 0.05 (2008), 1.4 (2006)
Total funding (M€) : n.a.
Last funding (M€) : 2.6
Focus : Cancers
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2013 .02 Financing (capital increase): 6.25 M€, with preemptive subscription rights for existing shareholders PBO [19 years]
2012 .11 Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in crohn's disease (end) CLIN [19 years]
2011 .11 Clinical trial (phase I/II) for TNFa-kinoid, a therapeutic vaccine in lupus (end) CLIN [18 years]
2011 .06 Financing (no interest loan) : 1.5 M€, by OSEO Innovation to support Tracker (follow-up of 2008 deal) DEBT [18 years]
2011 .04 Financing (capital increase): 2.25 M€ by Debiopharm, Truffle Venture and OTC Asset Management [followed in June by 0.4 M€, dedicated to foreign shareholders) PBO [18 years]
2010 .12 Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis (end, with promising results) CLIN [17 years]
2010 .04 Listing on Alternext : 10 M€ (IPO) PBO [17 years]
2009 .12 Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis patients failing TNFa monoclonal antibody therapy (beginning) CLIN [16 years]
2008 .11 Clinical trial (phase I-II) for TNFa-kinoid, a therapeutic vaccine for the treatment of TNFa dependent auto-immune diseases in South-Africa (beginning) CLIN [15 years]
2008 .10 Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), by OSEO Innovation to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics DEBT [15 years]
2007 .07 Round-financing : 13.0 M€, by Novartis and previous shareholders RFIN [14 years]
2006 .06 Licensing-out to Debiopharm with capital sharing LICOUT [13 years]
2006 .06 Nomination : Guy Fanneau de la Horie, as CEO ORGN [13 years]
2004 .10 Round-financing : 1.5 M€, by Truffle Ventures and 1.2 M€, by Anvar RFIN [11 years]
2003 .07 Nomination : Alain Huriez, as CEO (still, as Director, Truffle Venture) ORGN [10 years]
2003 .06 Round-financing : 3.5 M€, by Truffle Ventures and Europe Innovation (reaching 51% of capital) RFIN [10 years]
1999 .00 Licensing-out of HIV therapeutic vaccine to Aventis Pasteur LICOUT [5 years]
1998 .00 Nomination : Jean-François Bensahel, as CEO ORGN [4 years]
1993 .04 Company founded by Daniel Zagury (immunologist), as a spin-off from Pierre et Marie Curie Paris University ORGF [0 year]

Actualisation / Updating: 20-Feb-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende